The changing classification of myelodysplastic syndromes: what's in a name?

25Citations
Citations of this article
30Readers
Mendeley users who have this article in their library.

Abstract

What is the most sensible way of organizing the disorderly spectrum of acquired marrow failure states collectively known as the myelodysplastic syndromes (MDS)? While the 2008 version of the World Health Organization classification is the current standard, the recent proliferation of MDS prognostic tools illustrates the usefulness of supplemental information for clinical purposes. Many cases of acquired bone marrow failure do not fit cleanly into established MDS categories, yet an alternative diagnosis is not apparent. The term "idiopathic cytopenias of undetermined significance" (ICUS) has been proposed to describe these cases, but there is a paucity of information about the natural history of ICUS. New data on the natural history of MDS associated with a broad range of cytogenetic abnormalities that were not included in the International Prognostic Scoring System (IPSS), as well as the emerging picture of karyotypically occult DNA changes, promise to inform future classifications.

Cite

CITATION STYLE

APA

Steensma, D. P. (2009). The changing classification of myelodysplastic syndromes: what’s in a name? Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. https://doi.org/10.1182/asheducation-2009.1.645

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free